Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial
MM Redfield, HH Chen, BA Borlaug, MJ Semigran… - Jama, 2013 - jamanetwork.com
Importance Studies in experimental and human heart failure suggest that
phosphodiesterase-5 inhibitors may enhance cardiovascular function and thus exercise
capacity in heart failure with preserved ejection fraction (HFPEF). Objective To determine the
effect of the phosphodiesterase-5 inhibitor sildenafil compared with placebo on exercise
capacity and clinical status in HFPEF. Design Multicenter, double-blind, placebo-controlled,
parallel-group, randomized clinical trial of 216 stable outpatients with HF, ejection fraction≥ …
phosphodiesterase-5 inhibitors may enhance cardiovascular function and thus exercise
capacity in heart failure with preserved ejection fraction (HFPEF). Objective To determine the
effect of the phosphodiesterase-5 inhibitor sildenafil compared with placebo on exercise
capacity and clinical status in HFPEF. Design Multicenter, double-blind, placebo-controlled,
parallel-group, randomized clinical trial of 216 stable outpatients with HF, ejection fraction≥ …